Crossmark

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency

Crossref DOI link: https://doi.org/10.1007/s13300-020-00907-w

Published Online: 2020-08-27

Published Print: 2020-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raji, Annaswamy https://orcid.org/0000-0002-2430-8160
Xu, Zhi Jin

Lam, Raymond L. H.

O’Neill, Edward A.

Kaufman, Keith D.

Engel, Samuel S. https://orcid.org/0000-0002-4439-6356
Funding

Funding for this research was provided by:

Merck
License Information

Text and Data Mining valid from 2020-08-27

Version of Record valid from 2020-08-27
More Information

Article History

Received: 15 July 2020

First Online: 27 August 2020